333
Participants
Start Date
June 28, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2028
INT230-6
INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.
Eribulin
Eribulin IV
Trabectedin
Trabectedin infusion
Pazopanib
Pazopanib pill
Helios Klinikum Bad Saarow, Bad Saarow
University of Pennsylvania - Abramson Cancer Center, Philadelphia
Temple University - Fox Chase Cancer Center, Philadelphia
Duke Cancer Center, Durham
Centro Integral Oncologico Clara Campal (HM CIOCC), Madrid
The James Cancer Hospital and Solove Research Institute, Columbus
Profound Research LLC, Farmington Hills
Nebraska Methodist Hospital, Omaha
Centre Leon Berard, Lyon
USC/Norris Comprehensive Cancer Center, Los Angeles
Sarcoma Oncology Center, Santa Monica
University of California Los Angeles (UCLA) - Santa Monica Cancer Care, Santa Monica
Yale School of Medicine - Smilow Cancer Hospital - Yale - New Haven Hospital Location, New Haven
Princess Margaret Cancer Centre, Toronto
Universitäres Krebszentrum (UCCL), Leipzig
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Vall Hebron, Barcelona
Lead Sponsor
Collaborators (1)
Premier Research
OTHER
Intensity Therapeutics, Inc.
INDUSTRY